Oncocyte (IMDX) Competitors

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 55.3% of Oncocyte shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ARS Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

ARS Pharmaceuticals has a net margin of -200.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Oncocyte has lower revenue, but higher earnings than ARS Pharmaceuticals. Oncocyte is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

ARS Pharmaceuticals presently has a consensus target price of $28.20, suggesting a potential upside of 422.32%. Oncocyte has a consensus target price of $12.00, suggesting a potential upside of 133.24%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Oncocyte.

In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Oncocyte. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 0 mentions for Oncocyte. ARS Pharmaceuticals' average media sentiment score of 0.90 beat Oncocyte's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Aerovate Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Oncocyte currently has a consensus target price of $12.00, indicating a potential upside of 133.24%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts plainly believe Oncocyte is more favorable than Aerovate Therapeutics.

55.3% of Oncocyte shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncocyte has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Oncocyte's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Oncocyte has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oncocyte presently has a consensus price target of $12.00, indicating a potential upside of 133.24%. Tectonic Therapeutic has a consensus price target of $79.40, indicating a potential upside of 184.64%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Oncocyte.

Tectonic Therapeutic has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Oncocyte has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 0 mentions for Oncocyte. Tectonic Therapeutic's average media sentiment score of 0.83 beat Oncocyte's score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Oncocyte has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, meaning that its stock price is 221% more volatile than the broader market.

Shattuck Labs has lower revenue, but higher earnings than Oncocyte. Shattuck Labs is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

In the previous week, Oncocyte's average media sentiment score of 0.00 equaled Shattuck Labs'average media sentiment score.

Oncocyte has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Oncocyte currently has a consensus target price of $12.00, suggesting a potential upside of 133.24%. Shattuck Labs has a consensus target price of $12.63, suggesting a potential upside of 76.08%. Given Oncocyte's higher probable upside, equities analysts clearly believe Oncocyte is more favorable than Shattuck Labs.

55.3% of Oncocyte shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Comparatively, 8.8% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Shattuck Labs has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Shattuck Labs' return on equity.